Skip to main content
Clinical Trials/NCT02122133
NCT02122133
Terminated
Not Applicable

CARE: A Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400

Penumbra Inc.1 site in 1 country67 target enrollmentMay 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intracranial Aneurysms
Sponsor
Penumbra Inc.
Enrollment
67
Locations
1
Primary Endpoint
1. Acute radiation exposure [air kerma, kerma-area product (KAP) or dose area product (DAP), and fluoroscopic time].
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

The primary objective of this study is to gather data on the radiation exposure in patients treated with the Penumbra Coil 400™ System (PC 400) or conventional coils per their respective indications for use.This is a multicenter case review study of patients presenting with intracranial aneurysms who are treated with coil embolization therapy using the PC 400 or conventional coils. Data for each patient are collected acutely.Up to 90 patients treated with the PC 400 or conventional coils (2:1) at up to 15 centers in the USA will be enrolled.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
October 19, 2016
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients enrolled in the PC 400 arm must be those treated according to the cleared indication for the PC 400 System, which includes endovascular embolization of intracranial aneurysms.
  • Patients treated with conventional coils should be treated per their IFU.
  • Adjunctive use of stents, balloons or liquid embolics, if considered appropriate by investigators, is allowed.

Exclusion Criteria

  • Pre-planned use of multiple coil systems and/or flow diverters.

Outcomes

Primary Outcomes

1. Acute radiation exposure [air kerma, kerma-area product (KAP) or dose area product (DAP), and fluoroscopic time].

Time Frame: At immediate post-procedure

Radiation exposure is measured by air kerma, kerma-area product (KAP) or dose area product (DAP), and fluoroscopic time.

2. Procedural serious adverse events

Time Frame: Procedural serious adverse events up until 3 days or discharge, whichever occurs first.

Study Sites (1)

Loading locations...

Similar Trials